{"id":"NCT03772665","sponsor":"Kubota Vision Inc.","briefTitle":"Safety and Efficacy of Emixustat in Stargardt Disease","officialTitle":"A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-07","primaryCompletion":"2022-06-13","completion":"2022-06-23","firstPosted":"2018-12-11","resultsPosted":"2023-08-03","lastUpdate":"2024-05-30"},"enrollment":194,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Stargardt Disease"],"interventions":[{"type":"DRUG","name":"Emixustat","otherNames":["emixustat hydrochloride"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Emixustat","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease.\n\nFunding Source -- FDA OOPD","primaryOutcome":{"measure":"Mean Rate of Change in Total Area of Macular Atrophy, as Measured by Fundus Autofluorescence (FAF)","timeFrame":"24 months","effectByArm":[{"arm":"Emixustat","deltaMin":1.28,"sd":0.0783},{"arm":"Placebo","deltaMin":1.309,"sd":0.1002}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":29,"countries":["United States","Brazil","Canada","Denmark","France","Germany","Italy","Netherlands","South Africa","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":127},"commonTop":["Visual acuity reduced"]}}